

BICO Group Nomination Committee 2023 AGM appointed

It is hereby announced that BICO Group's major owners have appointed a Nomination Committee. The Annual General Meeting of BICO Group AB will be held on May 9, 2023.

In accordance with the decision by the Annual General Meeting 2022 and the most recently adopted principles regarding the composition of the nomination committee made 26 April 2021, the Nomination Committee of BICO Group AB shall consist of five members, one of whom shall be the Chairman of the Board. The four largest shareholders who wish to participate in the committee are entitled to appoint one member each. In preparation for the 2023 Annual General Meeting the members of the Nomination Committee have been appointed based on the ownership structure as per 30th of September 2022 and consists of:

- Mats Engström, nominated by Erik Gatenholm
- Claes Dinkelspiel, nominated by Héctor Martínez
- Malin Björkmo, nominated by Handelsbanken Fonder
- Jannis Kitsakis, nominated by Fourth Swedish National Pension Fund
- Carsten Browall, Chairman of the Board of BICO Group AB

The Nomination Committee will prepare proposals for the Annual General Meeting 2023 regarding election of chairman/woman and other directors of the board, election of auditor, matters regarding fees, election of chairman/woman of the Annual General Meeting and resolution concerning the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee ahead of the Annual General Meeting 2023 are welcome to contact the Nomination Committee by email to: ir@bico.com. Please write "To the Nomination Committee" in the subject line.

or per mail to:
BICO Group AB
Långfilsgatan 9
412 77 Göteborg
Sweden

Proposals shall be submitted in writing in due time before the Annual General Meeting, no later than 10 February 2023, to ensure that the proposals can be considered by the Nomination Committee.

For further information, please contact:

Carsten Brovall, Chairman of the Board of Directors, BICO Group AB
Email: cb@bico.com

Åsa Hillsten, SVP & Head of Investor Relations, BICO Group AB
Phone: +46 70-081 81 17
Email: ash@bico.com

The information was submitted for publication, through the agency of the contact persons set out above, on 28 October 2022, at 14.00 CET.

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world's leading bioconvergence company, with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives. Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Attachments

[BICO Group Nomination Committee 2023 AGM appointed](#)